William J. Rifkin, Rami S. Kantar, MD, Safi Ali-Khan, Natalie M. Plana, J. Rodrigo Diaz-Siso, MD, Manos Tsakiris, PhD, MSc, and Eduardo D. Rodriguez, MD, DDS
Facial transplantation provides a viable option for those patients with severe facial defects who are more likely to adapt to their new facial appearance.
AMA J Ethics. 2018;20(4):309-323. doi:
10.1001/journalofethics.2018.20.4.peer1-1804.
Using the patient’s worldview to challenge his or her decision and establish a treatment plan—implying the view is shared by the physician when it is not—could be seen as manipulative and deceptive.
Tina K. Sacks, PhD, Katie Savin, MSW, and Quenette L. Walton, PhD, LCSW
Would you question health decisions made by a 37-year old Black woman whose great-grandfather died in the US Public Health Service Syphilis Study at Tuskegee?
AMA J Ethics. 2021;23(2):E183-188. doi:
10.1001/amajethics.2021.183.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"